The FDA has approved the first biologic therapy for patients with moderate to severe Crohn’s disease who have failed, or were intolerant to, one or more treatments containing immunomodulators, corticosteroids or tumor necrosis factor (TNF) blockers.
Ustekinumab (Stelara, Janssen Biotech) is the only treatment for Crohn’s disease that consists of a one-time intravenous induction injection (250, 390 or 520 mg) that helps reduce symptoms, and a dosage of 90 mg every eight weeks to